×
About 128 results
Two uveitis treatment options yield similar success
https://www.mdedge.com/internalmedicine/article/207854/ankylosing-spondylitis/two-uveitis-treatment-options-yield-similar/page/0/1?channel=39313

Sep 10th, 2019 - Overall, 64 patients given methotrexate (67%) and 56 of those given mycophenolate (57%) achieved treatment success at 6 months. Treatment success included inflammation control defined as “less than or equal to 0.

New Age-Related Macular Degeneration Common in Untreated Fellow Eyes
https://www.medscape.com/viewarticle/915760

Jul 17th, 2019 - NEW YORK (Reuters Health) - New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies. "Patients with neovascular AMD in one eye should be followed regularly to check for subtle clinical and imaging findings indicating conversion ...

Calcified Nodules Linked to AMD Progression
https://www.medscape.com/viewarticle/904649

Nov 7th, 2018 - The presence of a specific type of calcified nodule in the retinal drusen of patients with age-related macular degeneration (AMD) is associated with a more than sixfold increased risk for late-stage progression of the disease, a study has shown. In a cohort of patients with AMD, progression to advanced AMD was observed in those who had histological and imaging evidence of sprawling patterns of ...

Compliance in the Management of Diabetic Retinopathy: The Reality and Risk of Loss to Follow-up
https://www.medscape.com/viewarticle/899649

Jul 26th, 2018 - Diabetes mellitus affects approximately 30 million people in the United States, or nearly 10% of the US population.[1] Diabetic retinopathy (DR)—retinal microvascular damage due to chronic hyperglycemia—is a leading cause of vision loss and ultimate blindness.[2,3] DR is classified clinically as nonproliferative or proliferative. Vision loss in nonproliferative DR is often secondary to vessel l...

Vitreous Hemorrhage in the Setting of a Vascular Loop
https://www.mdedge.com/fedprac/article/167470/dvt/vte/vitreous-hemorrhage-setting-vascular-loop?channel=45
Joy Huang, OD, Paul B. Greenberg, MD, MPH et. al.

Jun 17th, 2018 - Vascular loops are rare congenital optic nerve anomalies that originate from the arterial or venous circulation; 90% arise from the arterial circulation. 1 Vascular loops are usually asymptomatic unless an arterial or venous occlusion, hyphema, and vitreous or preretinal hemorrhage should arise.

June 2018 Digital Edition
https://www.mdedge.com/fedprac/article/168304/june-2018-digital-edition?channel=27011

Jun 1st, 2018 - Click here to access the June 2018 Digital Edition. Table of Contents Setting and Method of Measurement Affect Blood Pressure Readings Workforce Assessment of VA Home-Based Primary Care Pharmacists Using Simulation to Enhance Care of Older Veterans Effect of High-Dose Ergocalciferol on Rate of Falls Vitreous Hemorrhage in the Setting of a Vascular Loop Nephrogenic Systemic Fibrosis in a Patient.

YAG Laser Treats Symptomatic Vitreous Floaters
https://www.medscape.com/viewarticle/887372

Oct 19th, 2017 - YAG laser vitreolysis effectively treated symptomatic vitreous floaters, according to a report published in the September issue of JAMA Ophthalmology. Posterior vitreous detachment occurs in 65% of patients aged 65 years or older. It may be associated with accumulation of fibrous tissue into a Weiss ring, which hovers above the optic nerve and casts shadows onto the retina, producing large floa...

Laser Treatment Appears to Reduce Eye Floater Symptoms
https://www.medpagetoday.com/ophthalmology/generalophthalmology/66821

Jul 23rd, 2017 - Action Points Note that this small randomized trial in patients with vitreous floaters lent support to the use of laser vitreolysis for the treatment of a subset of floaters known as Weiss Rings. The control group received sham laser treatment, not vitrectomy, which is a commonly-used procedure for this condition. Patients treated with YAG laser vitreolysis reported significantly improved sympt...

Anti-VEGF Therapy Improved Diabetic Retinopathy in DME
https://www.medpagetoday.com/ophthalmology/generalophthalmology/64847

Apr 27th, 2017 - Action Points Note that this small randomized trial found that all anti-VEGF intravitreous therapies were effective for diabetic retinopathy, though aflibercept and ranibizumab performed slightly better than bevacizumab. The use of intra-vitreous anti-VEGF therapy represents a paradigm shift in treatment away from photocoagulation. Anti-vascular endothelial growth factor (anti-VEGF) therapy not...

Proliferative Vitreoretinopathy and Steroid Implants -- A Good Fit?
https://www.medscape.com/viewarticle/878376

Apr 12th, 2017 - Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial Banerjee PJ, Quartilho A, Bunce C, et al Ophthalmology. 2017 Feb 22. [Epub ahead of print] Reports for the use of steroids in the management of proliferative vitreoretinopathy (PVR) are inconsistent. The advent of a sustained-release implant that can release dexamethasone for 3-4 m...

Intravitreal Dexamethasone Implant Improves CME in Patients With Quiescent Uveitis
https://www.medscape.com/viewarticle/873738

Dec 26th, 2016 - A sustained release intravitreal dexamethasone (DEX) implant may be an effective treatment for patients with persistent cystoid macular edema (CME) despite well-controlled uveitis. These findings were published online November 23 in Retina. "Thirty days after the first treatment with DEX implant, the mean increase in [best corrected visual acuity (BCVA)] was approximately 15 letters and this imp...

Intravitreal sirolimus proves effective in reducing noninfectious uveitis inflammation
https://www.mdedge.com/rheumatology/article/116845/spondyloarthropathies/intravitreal-sirolimus-proves-effective-reducing?channel=27970
Whitney McKnight

Oct 31st, 2016 - Intravitreal sirolimus 440 mcg or 880 mcg administered on days 1, 60, and 120, was shown to significantly improve ocular inflammation with preservation of best-corrected visual acuity in patients with noninfectious uveitis of the posterior segment, a phase III study has shown. In the multinational SAKURA (Study Assessing Double-masked Uveitis Treatment) study, 346 study eyes were analyzed in th.

Vitreous Injection New Option for Postoperative Cataract Care
https://www.medscape.com/viewarticle/866812

Jul 27th, 2016 - In an effort to overcome issues with noncompliance, a new study evaluated the efficacy of transzonular vitreous injection compared with standard topical therapy after cataract surgery and found outcomes between the two methods to be similar. These study findings were published online July 18 in Clinical Ophthalmology. "The results in the current study suggest that patients receiving the combina...

Sleep Patterns Linked to Macular Disease
https://www.medscape.com/viewarticle/859177

Feb 21st, 2016 - Too much sleep may be tied to retinal problems, a new study suggests. Adult patients of a retina practice with a diagnosis of geographic atrophy secondary to age-related macular degeneration (AMD) were significantly more likely than those without the condition to report sleeping more than 8 hours per night. Further, patients who reported sleeping more than 8 hours per night had a sevenfold incr...

Proliferative Diabetic Retinopathy: Should New Data Change Management?
https://www.medscape.com/viewarticle/856665

Jan 6th, 2016 - Beyond Standard of Care Diabetic retinopathy (DR) is a leading cause of vision loss around the world, and remains the most common cause of blindness among working-age people in the United States and many developed countries.[1] Largely mediated through pathologic retinal ischemia, DR leads to vision loss primarily through diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR)...

Squalamine Boosts Anti-VEGF Effect in Macular Degeneration
https://www.medscape.com/viewarticle/854621

Nov 16th, 2015 - LAS VEGAS — In patients with neovascular age-related macular degeneration and classic-containing lesions, the addition of 2% squalamine lactate ophthalmic solution (OHR-102, Ohr Pharmaceutical) to ranibizumab increased visual acuity, according to a phase 2 study. "The IMPACT study showed robust vision gains with the combination of squalamine lactate and ranibizumab in classic-containing lesions...

Diabetic Macular Edema: Is Your Patient Going Blind?
https://www.mdedge.com/fedprac/article/104237/diabetes/diabetic-macular-edema-your-patient-going-blind/page/0/3?channel=205

Nov 11th, 2015 - As aforementioned, VEGF causes increased vascular permeability and breakdown of the blood-retinal barrier. Patients with DME have been shown to have increased levels of VEGF in the vitreous when compared with nondiabetic controls.

Noninvasive Tool Can Help Assess Diabetic Retinopathy Progression
https://www.medscape.com/viewarticle/853623

Nov 2nd, 2015 - NEW YORK (Reuters Health) - A new algorithm may provide a quick noninvasive tool to measure diabetic retinopathy progression and individualize patient treatment, researchers report. They developed an algorithm to quantify the vitreous hyperreflective foci (VHRF) found in standard three-dimensional optical coherence tomographic (OCT) scans. Compared with patients with diabetes but no diabetic ma...

Ranibizumab Effective for Pigment Epithelial Detachment
https://www.medscape.com/viewarticle/848286

Jul 16th, 2015 - VIENNA — Pigment epithelial detachments of any size can be effectively treated with low-dose ranibizumab (Lucentis, Genentech) in patients with subfoveal neovascular age-related macular degeneration, according to an analysis of data from the phase 3 HARBOR study. Even when the dose of the VEGF inhibitor was quadrupled, "no additional benefit was seen," said David Eichenbaum, MD, from Retina Vit...

Laser Resensitizes Eyes to Anti-VEGF Treatment in AMD
https://www.medscape.com/viewarticle/848049

Jul 14th, 2015 - A type of laser known as subthreshold diode micropulse laser (SDM) therapy restores sensitivity to inhibitors of vascular endothelial growth factor (VEGF) for treatment in patients with neovascular age-related macular degeneration (AMD) whose eyes no longer respond to treatment, new research shows. "SDM is simple and exceedingly safe. It has no known side effects or adverse treatment effects, p...